South African strain

[jon-nyc]

Previous infection seems not to offer protection from infection with new strain - at all. (Though maybe severity?)

But what is even more ominous is preliminary data from Novovax trial in South Africa. Previous infection did not protect against reinfection with variant strain: rates of COVID-19 among placebo group 7 days post-dose 1:
Seronegative: 3.9% (58/1494)
Seropositive: 3.9% (26/674)
7/

[Doctor Phibes]

Fear not, the superior British strain will defeat the pathetic South African strain.